Literature DB >> 19679545

Melanoma proliferation and chemoresistance controlled by the DEK oncogene.

Michael S Khodadoust1, Monique Verhaegen, Ferdinand Kappes, Erica Riveiro-Falkenbach, Juan C Cigudosa, David S L Kim, Arul M Chinnaiyan, David M Markovitz, María S Soengas.   

Abstract

Gain of chromosome 6p is a consistent feature of advanced melanomas. However, the identity of putative oncogene(s) associated with this amplification has remained elusive. The chromatin remodeling factor DEK is an attractive candidate as it maps to 6p (within common melanoma-amplified loci). Moreover, DEK expression is increased in metastatic melanomas, although the functional relevance of this induction remains unclear. Importantly, in other tumor types, DEK can display various tumorigenic effects in part through its ability to promote proliferation and inhibit p53-dependent apoptosis. Here, we report a generalized up-regulation of DEK protein in aggressive melanoma cells and tumors. In addition, we provide genetic and mechanistic evidence to support a key role of DEK in the maintenance of malignant phenotypes of melanoma cells. Specifically, we show that long-term DEK down-regulation by independent short hairpin RNAs resulted in premature senescence of a variety of melanoma cell lines. Short-term abrogation of DEK expression was also functionally relevant, as it attenuated the traditional resistance of melanomas to DNA-damaging agents. Unexpectedly, DEK short hairpin RNA had no effect on p53 levels or p53-dependent apoptosis. Instead, we identified a new role for DEK in the transcriptional activation of the antiapoptotic MCL-1. Other MCL-1-related factors such as BCL-2 or BCL-xL were unaffected by changes in the endogenous levels of DEK, indicating a selective effect of this gene on the apoptotic machinery of melanoma cells. These results provide support for DEK as a long sought-after oncogene mapping at chromosome 6, with novel functions in melanoma proliferation and chemoresistance.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19679545      PMCID: PMC2727675          DOI: 10.1158/0008-5472.CAN-09-1063

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  49 in total

1.  Enhanced killing of melanoma cells by simultaneously targeting Mcl-1 and NOXA.

Authors:  Jian-Zhong Qin; Hong Xin; Leonid A Sitailo; Mitchell F Denning; Brian J Nickoloff
Journal:  Cancer Res       Date:  2006-10-01       Impact factor: 12.701

2.  Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins.

Authors:  Guoping Wang; Zaneta Nikolovska-Coleska; Chao-Yie Yang; Renxiao Wang; Guozhi Tang; Jie Guo; Sanjeev Shangary; Su Qiu; Wei Gao; Dajun Yang; Jennifer Meagher; Jeanne Stuckey; Krzysztof Krajewski; Sheng Jiang; Peter P Roller; Hatice Ozel Abaan; York Tomita; Shaomeng Wang
Journal:  J Med Chem       Date:  2006-10-19       Impact factor: 7.446

3.  DEK Expression is controlled by E2F and deregulated in diverse tumor types.

Authors:  Maria Stella Carro; Fabio Mario Spiga; Micaela Quarto; Valentina Di Ninni; Sara Volorio; Myriam Alcalay; Heiko Müller
Journal:  Cell Cycle       Date:  2006-06-01       Impact factor: 4.534

4.  Distinct sets of genetic alterations in melanoma.

Authors:  John A Curtin; Jane Fridlyand; Toshiro Kageshita; Hetal N Patel; Klaus J Busam; Heinz Kutzner; Kwang-Hyun Cho; Setsuya Aiba; Eva-Bettina Bröcker; Philip E LeBoit; Dan Pinkel; Boris C Bastian
Journal:  N Engl J Med       Date:  2005-11-17       Impact factor: 91.245

5.  Apoptosis inhibition by the human DEK oncoprotein involves interference with p53 functions.

Authors:  Trisha M Wise-Draper; Hillary V Allen; Elizabeth E Jones; Kristen B Habash; Hiroshi Matsuo; Susanne I Wells
Journal:  Mol Cell Biol       Date:  2006-08-07       Impact factor: 4.272

Review 6.  Malignant melanoma: genetics and therapeutics in the genomic era.

Authors:  Lynda Chin; Levi A Garraway; David E Fisher
Journal:  Genes Dev       Date:  2006-08-15       Impact factor: 11.361

7.  A novel BH3 mimetic reveals a mitogen-activated protein kinase-dependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species.

Authors:  Monique Verhaegen; Joshua A Bauer; Cristina Martín de la Vega; Guoping Wang; Keith G Wolter; J Chadwick Brenner; Zaneta Nikolovska-Coleska; Audrey Bengtson; Rajan Nair; James T Elder; Matt Van Brocklin; Thomas E Carey; Carol R Bradford; Shaomeng Wang; María S Soengas
Journal:  Cancer Res       Date:  2006-12-01       Impact factor: 12.701

8.  Negative regulation of the RelA/p65 transactivation function by the product of the DEK proto-oncogene.

Authors:  Morgan Sammons; Shan Shan Wan; Nancy L Vogel; Edwin J Mientjes; Gerard Grosveld; Brian P Ashburner
Journal:  J Biol Chem       Date:  2006-07-07       Impact factor: 5.157

9.  Anti-oncogenic role of the endoplasmic reticulum differentially activated by mutations in the MAPK pathway.

Authors:  Christophe Denoyelle; George Abou-Rjaily; Vladimir Bezrookove; Monique Verhaegen; Timothy M Johnson; Douglas R Fullen; Jenny N Pointer; Stephen B Gruber; Lyndon D Su; Mikhail A Nikiforov; Randal J Kaufman; Boris C Bastian; Maria S Soengas
Journal:  Nat Cell Biol       Date:  2006-09-10       Impact factor: 28.824

Review 10.  NF-kappaB activation in melanoma.

Authors:  Yukiko Ueda; Ann Richmond
Journal:  Pigment Cell Res       Date:  2006-04
View more
  70 in total

Review 1.  Pathways of oncogene-induced senescence in human melanocytic cells.

Authors:  Rajat Bansal; Mikhail A Nikiforov
Journal:  Cell Cycle       Date:  2010-07-03       Impact factor: 4.534

Review 2.  Control of tumorigenesis and chemoresistance by the DEK oncogene.

Authors:  Erica Riveiro-Falkenbach; María S Soengas
Journal:  Clin Cancer Res       Date:  2010-05-25       Impact factor: 12.531

3.  DEK in the synovium of patients with juvenile idiopathic arthritis: characterization of DEK antibodies and posttranslational modification of the DEK autoantigen.

Authors:  Nirit Mor-Vaknin; Ferdinand Kappes; Amalie E Dick; Maureen Legendre; Catalina Damoc; Seagal Teitz-Tennenbaum; Roland Kwok; Elisa Ferrando-May; Barbara S Adams; David M Markovitz
Journal:  Arthritis Rheum       Date:  2011-02

4.  The nuclear DEK interactome supports multi-functionality.

Authors:  Eric A Smith; Eric F Krumpelbeck; Anil G Jegga; Malte Prell; Marie M Matrka; Ferdinand Kappes; Kenneth D Greis; Abdullah M Ali; Amom R Meetei; Susanne I Wells
Journal:  Proteins       Date:  2017-11-11

5.  The potential predictive value of DEK expression for neoadjuvant chemoradiotherapy response in locally advanced rectal cancer.

Authors:  J Martinez-Useros; I Moreno; M J Fernandez-Aceñero; M Rodriguez-Remirez; A Borrero-Palacios; A Cebrian; T Gomez Del Pulgar; L Del Puerto-Nevado; W Li; A Puime-Otin; N Perez; M S Soengas; J Garcia-Foncillas
Journal:  BMC Cancer       Date:  2018-02-06       Impact factor: 4.430

Review 6.  The DEK oncoprotein and its emerging roles in gene regulation.

Authors:  C Sandén; U Gullberg
Journal:  Leukemia       Date:  2015-03-13       Impact factor: 11.528

7.  Intercellular trafficking of the nuclear oncoprotein DEK.

Authors:  Anjan K Saha; Ferdinand Kappes; Amruta Mundade; Anja Deutzmann; David M Rosmarin; Maureen Legendre; Nicolas Chatain; Zeina Al-Obaidi; Barbara S Adams; Hidde L Ploegh; Elisa Ferrando-May; Nirit Mor-Vaknin; David M Markovitz
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-08       Impact factor: 11.205

8.  DEK regulates hematopoietic stem engraftment and progenitor cell proliferation.

Authors:  Hal E Broxmeyer; Ferdinand Kappes; Nirit Mor-Vaknin; Maureen Legendre; John Kinzfogl; Scott Cooper; Giao Hangoc; David M Markovitz
Journal:  Stem Cells Dev       Date:  2011-10-27       Impact factor: 3.272

9.  The human oncoprotein and chromatin architectural factor DEK counteracts DNA replication stress.

Authors:  A Deutzmann; M Ganz; F Schönenberger; J Vervoorts; F Kappes; E Ferrando-May
Journal:  Oncogene       Date:  2014-10-27       Impact factor: 9.867

Review 10.  Stacking the DEK: from chromatin topology to cancer stem cells.

Authors:  Lisa M Privette Vinnedge; Ferdinand Kappes; Nicolas Nassar; Susanne I Wells
Journal:  Cell Cycle       Date:  2012-12-19       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.